ARRY - Array BioPharma Inc Stock Price, Fair Value and News

$5.63+0.29 (+5.43%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ARRY Price Action

Last 7 days

1.8%

Last 30 days

-11.6%

Last 90 days

-12.2%

Trailing 12 Months

-67.5%

ARRY RSI Chart

ARRY Valuation

Market Cap

855.4M

Price/Earnings (Trailing)

-9.09

Price/Sales (Trailing)

0.87

EV/EBITDA

-499.42

Price/Free Cashflow

4.77

ARRY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ARRY Fundamentals

ARRY Revenue

Revenue (TTM)

982.2M

Rev. Growth (Yr)

-33.97%

Rev. Growth (Qtr)

-9.52%

ARRY Earnings

Earnings (TTM)

-94.1M

Earnings Growth (Yr)

-711.98%

Earnings Growth (Qtr)

-650.06%

ARRY Profitability

Operating Margin

30.91%

EBT Margin

-7.96%

Return on Equity

-146%

Return on Assets

-6.02%

Free Cashflow Yield

20.97%

ARRY Investor Care

Shares Dilution (1Y)

0.48%

Diluted EPS (TTM)

-0.97

ARRY Alerts

2 major insider buys recently.
GOLDMAN SACHS GROUP INC reported owning 5.6% of ARRY [2024-11-12]
Big fall in Revenue (Y/Y)
Big fall in earnings (Y/Y)
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.4B	1.1B	982.2M	0
2023	1.7B	1.8B	1.6B	1.6B
2022	905.7M	1.1B	1.5B	1.6B
2021	683.2M	764.8M	814.0M	853.3M
2020	704.1M	760.3M	816.5M	872.7M
2019	0	0	469.3M	647.9M
2018	0	0	0	290.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Array BioPharma Inc

Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products include DuraTrack HZ v3, a single axis tracker; Array STI H250 to deliver a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance its energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.

CEO	Mr. Kevin G. Hostetler
WEBSITE	https://arraytechinc.com
SECTOR	Technology
INDUSTRY	Solar
EMPLOYEES	1096

Array BioPharma Inc Frequently Asked Questions

What is the ticker symbol for Array BioPharma Inc? What does ARRY stand for in stocks?

ARRY is the stock ticker symbol of Array BioPharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Array BioPharma Inc (ARRY)?

As of Fri Dec 20 2024, market cap of Array BioPharma Inc is 855.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARRY stock?

You can check ARRY's fair value in chart for subscribers.

Is Array BioPharma Inc a good stock to buy?

The fair value guage provides a quick view whether ARRY is over valued or under valued. Whether Array BioPharma Inc is cheap or expensive depends on the assumptions which impact Array BioPharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARRY.

What is Array BioPharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ARRY's PE ratio (Price to Earnings) is -9.09 and Price to Sales (PS) ratio is 0.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARRY PE ratio will change depending on the future growth rate expectations of investors.